Elevated cholesterol levels of atherogenic lipoproteins as a result of lipid metabolism disorders are one of the main risk factors for coronary atherosclerosis, coronary heart disease, heart attack and stroke. Low–density lipoprotein apheresis (LDL apheresis) is an effective method of reducing the concentration of atherogenic lipoprotein cholesterol in cases where drug therapy is not effective enough or there are contraindications to its use. The use of modern lipid-lowering drugs has significantly reduced the level of LDL cholesterol in the population, therefore LDL apheresis is relevant only for a number of particularly severe cases of atherosclerosis.

Unlike LDL, the concentration of Lp (a) in blood plasma is genetically determined and resistant to existing drug treatment, including the modern generation of statins, as well as to non-pharmacological approaches related to lifestyle changes and diet.

As recent studies have shown the increased level of Lp (a) more than 50 mg/dl, widespread among the population, is the leading cause of atherosclerosis development. Currently the only and most effective approach to correcting the Lp (a) level is efferent therapy methods that allow to remove up to 88% of Lp (a) circulating in plasma.